{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T10:33:05Z","timestamp":1756463585137},"reference-count":21,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2011,11,1]],"date-time":"2011-11-01T00:00:00Z","timestamp":1320105600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostic Cytopathology"],"published-print":{"date-parts":[[2012,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>BD FocalPoint GS\u2122 computer\u2010assisted screening of BD SurePath\u00ae liquid\u2010based cervical cytology slides (SP + FP) was compared with screening an accompanying conventional cervical Papanicolaou (Pap) smear (CON) in a split sample trial of 2,198 routine specimens. The rate of unsatisfactory specimens in the SP + FP arm was 0.2% compared with 4.1% in the conventional Pap smear, a significant reduction. There was no statistically significant difference between SP + FP and CON for the detection of histologically confirmed high\u2010grade (HG) lesions in the routine split sample specimens (<jats:italic>n<\/jats:italic> = 9). To further test the sensitivity of SP + FP for HG lesions, 38 SurePath slides from confirmed HG cases, without an accompanying CON, were interpolated among the routine smears. In every one of the 47 confirmed HG cases, either HG cells were present in the microscope fields selected by FocalPointGS\u2122 for review by the screening cytologist (46 of 47), or full screening of the slide was indicated by the FocalPointGS\u2122 (1 of 47), confirming the effectiveness of SP + FP technology for primary screening. In a small number of cases, the screening cytologist did not recognize the abnormality even though on review HG cells were present in fields selected by FocalPointGS\u2122. The overall detection rate was 93% for HG squamous lesions; 89% for known HG endocervical glandular lesions; and 91% for known endometrial carcinoma. In conclusion, the SP + FP detected 100% of HG abnormalities in the trial set; significantly reduced the rate of unsatisfactory specimens; and improved the overall screening rate of detection of HG abnormalities particularly of glandular lesions when compared with other screening technologies. Diagn. Cytopathol. 2012. \u00a9 2011 Wiley Periodicals, Inc.<\/jats:p>","DOI":"10.1002\/dc.21848","type":"journal-article","created":{"date-parts":[[2011,11,1]],"date-time":"2011-11-01T13:39:09Z","timestamp":1320154749000},"page":"1093-1099","source":"Crossref","is-referenced-by-count":7,"title":["Results of an Australian trial using SurePath liquid\u2010based cervical cytology with Focalpoint computer\u2010assisted screening technology"],"prefix":"10.1002","volume":"40","author":[{"given":"Ron C.","family":"Bowditch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanne M.","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Phillip J.","family":"Baird","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Merle L.","family":"Greenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,11]]},"reference":[{"key":"e_1_2_6_2_2","unstructured":"http:\/\/www.fda.gov\/MedicalDevices\/ProductsandMedicalProcedures\/DeviceApprovalsandClearances\/Recently\u2010ApprovedDevices\/ucm 125500.htm. Accessed 10 March 2011."},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/dc.20607"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20599"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/dc.10358"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1309\/AJCP8VE7AWBZCVQT"},{"key":"e_1_2_6_7_2","unstructured":"Medical Services Advisory Committee. Application 1122. Australian Government. Department of Health and Aging 2009; Available at:http:\/\/www.msac.gov.au\/internet\/msac\/publishing.nsf\/Content\/app1122\u20131. Accessed on 7 October 2009."},{"key":"e_1_2_6_8_2","unstructured":"TriPath Imaging\u00ae Inc. PrepStain\u00aeSystem Product Insert. Doc. No. 779\u201010002\u201003."},{"key":"e_1_2_6_9_2","unstructured":"BD FocalPoint\u2122 GS Imaging System Product Insert. BD Doc.No. 779\u201006922\u201000 Rev A 11\/08."},{"key":"e_1_2_6_10_2","unstructured":"National Cervical Screening Program Screening to Prevent Cervical Cancer: Guidelines for the Management of Asymptomatic Women with Screen Detected Abnormalities. Australian Government. National Health and Medical Research Council 2005; p19\u201325."},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/dc.20600"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23117"},{"key":"e_1_2_6_13_2","unstructured":"National Cervical Screening Programme. Screening to Prevent Cervical Cancer: Guidelines for the Management of Asymptomatic Women with Screen Detected Abnormalities. Appendix 8."},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.pap.0000184174.76221.eb"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2303.2008.00621.x"},{"key":"e_1_2_6_16_2","first-page":"466","article-title":"Evaluation of the ThinPrep Pap test as an adjunct to the conventional Pap smear","volume":"167","author":"Roberts JM","year":"1997","journal-title":"MJA"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39219.645475.55"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21425"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2303.1997.42375423.x"},{"key":"e_1_2_6_20_2","isbn-type":"print","volume-title":"NSW Cervical Screening Program. Challenges in Cytology: Confronting Difficult High Grade Lesions","author":"Bowditch RC","year":"2002","ISBN":"http:\/\/id.crossref.org\/isbn\/174080029X"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2303.2008.00618.x"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1159\/000330871"}],"container-title":["Diagnostic Cytopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fdc.21848","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/dc.21848","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T21:25:47Z","timestamp":1696973147000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/dc.21848"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11]]},"references-count":21,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["10.1002\/dc.21848"],"URL":"https:\/\/doi.org\/10.1002\/dc.21848","archive":["Portico"],"relation":{},"ISSN":["8755-1039","1097-0339"],"issn-type":[{"value":"8755-1039","type":"print"},{"value":"1097-0339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,11]]}}}